Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

BPR in the Pharmaceutical… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

BPR in the Pharmaceutical Industry

Doktorsavhandling
Författare Kai Artur Simon
Förlagsort Göteborg
Publiceringsår 2003
Publicerad vid Institutionen för tillämpad informationsteknologi (GU)
Språk en
Länkar hdl.handle.net/2077/909
Ämnesord BPR, pharmaceutical industry, clinical R&D
Ämneskategorier

Sammanfattning

This thesis investigates the use of Business Process Reengineering (BPR) as a change approach in the Pharmaceutical Industry. The pharmaceutical industry is undergoing profound changes. New opportunities, e.g. in the field of bio-technology, price pressure from governments, insurances and through generic products have created a variety of dynamics in the industry. Today, pharma-companies are also closely monitored with regard to their R&D pipeline and their ability to execute efficient R&D projects. As a result, pharma-companies have been looking for approaches that would enable a substantial improvement of their R&D processes, among them Business Process Reengineering. During a study at Astra Hässle in Mölndal, a research subsidiary of Astra (now AstraZeneca), two change initiatives under the label of BPR were investigated and analyzed. The first one, FASTRAC, was a local project, aiming at improving research and development at Astra Hässle. CANDELA, the second initiative, was aiming at an overhaul of R&D at Astra corporate level. FASTRAC resulted in several IT initiatives, of which one was investigated in detail. This investigation identified several critical aspects of the implementation of a new data collection process and IT-solution for remote data capture (RDC). Furthermore, this thesis proposes measures that go beyond the concept of reengineering. It proposes a new conceptual model for clinical research and suggests a different way of technology use for supporting the clinical R&D process. It also describes organizational aspects of organizing R&D in alternative ways.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?